Loading ...

Type 1 Diabetes Immunotherapy Using Polyclonal Tregs

(

JDRF Treg

)

ITN Protocol #:

ITN819AI

Branded Name:

JDRF Treg

ClinicalTrials.Gov ID:

Treatment Protocol #:

T Reg

Therapeutic Area:

Type 1 Diabetes

Current Status:

Completed

Summary:

A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes

Clinical Operations Manager

ITN Biostat

ITN Clinical Trial Physician

Study Personnel:

Protocol Chair

Stephen Gitelman, MDsgitelma@peds.ucsf.edu

Work: 

415-476-3748

Protocol Chair

Jeffrey Bluestone, PhDjeff.bluestone@ucsf.edu

Work: 

415-476-4451

Protocol Chair

Carol Soppecsoppe@immunetolerance.org

Work: 

415-353-4879

Protocol Chair

Noha Lim, PhDnlim@immunetolerance.org

Work: 

240-235-6151

Protocol Chair

Srinath Sanda, MDssanda@immunetolerance.org

Work: 

415-353-4414